RECORD // Company

Xencor Inc

Built 2026-11-21T23:58:00Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
  • Xencor, Inc. · legal entity in this company's GLEIF ownership tree (LEI 549300V5IF65437JKG30)
SEC EDGAR (1)
  • Xencor Inc · the SEC registrant record of this company
Matched by name only, not merged (4)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Xencor, Inc. · Ct business · same registered legal name as 'Xencor Inc' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Xencor, Inc. · Ctgov · same registered legal name as 'Xencor Inc' Possible match based on name, not a shared identifier. Compare the records. Compare
  • XENCOR · Epa echo · exact name match to 'Xencor Inc' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • XENCOR INC · Epa echo · same registered legal name as 'Xencor Inc' Possible match based on name, not a shared identifier. Compare the records. Compare

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001326732-26-000063

ItemValuePeriodFormFiledAccessionReport
Revenue$116,520,0003 months ended 2026-09-3010-Q2026-11-040001326732-26-0000632026-11-21 23:58 UTCReport an error
Net income (loss)$39,436,0003 months ended 2026-09-3010-Q2026-11-040001326732-26-0000632026-11-21 23:58 UTCReport an error
Interest expense$4,114,0003 months ended 2026-09-3010-Q2026-11-040001326732-26-0000632026-11-21 23:58 UTCReport an error
Cash and cash equivalents$59,622,000at 2026-09-3010-Q2026-11-040001326732-26-0000632026-11-21 23:58 UTCReport an error
Contract liabilities (total)$0at 2026-09-3010-Q2026-11-040001326732-26-0000632026-11-21 23:58 UTCReport an error

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001326732
Ticker
XNCR
EIN
201622502
CUSIP
98401F105
Record ID
sx:sec:0001326732

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

47 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
Business address465 N. HALSTEAD ST., SUITE 200, PASADENA, CA, 911072026-11-16SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$125,576,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 23:58 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-91,923,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 23:58 UTCReport an error
Total assets (at 2025-12-31)$875,495,0002025-12-3110-K, XBRL Assets2026-11-21 23:58 UTCReport an error
Stockholders' equity (at 2025-12-31)$635,587,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 23:58 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$54,073,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 23:58 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-135,117,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 23:58 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$3,150,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 23:58 UTCReport an error
Long-term debt (at 2025-12-31)$76,482,0002025-12-3110-K, XBRL LongTermDebtNoncurrent2026-11-21 23:58 UTCReport an error
Operating lease liabilities (at 2025-12-31)$67,998,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 23:58 UTCReport an error
Form D total offering amount (D filed 2021-11-19)$25,000,0002021-11-19D2026-11-21 23:58 UTCReport an error
Form D total amount sold (D filed 2021-11-19)$25,000,0002021-11-19D2026-11-21 23:58 UTCReport an error
Form D industry groupBiotechnology2021-11-19D2026-11-21 23:58 UTCReport an error
Form D revenue rangeDecline to Disclose2021-11-19D2026-11-21 23:58 UTCReport an error
Form D date of first sale2021-11-122021-11-19D2026-11-21 23:58 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-04)On November 4, 2026, Xencor, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2026 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in “Item 2.02. Results of Operations and Financial Condition” of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as…2026-11-04SEC EDGAR 8-K 0001326732-26-000062 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
8-K Item 2.02, Results of Operations and Financial (filed 2026-10-26)Condition. Based on current operating plans, Xencor, Inc. (the “Company”) expects to have cash to fund research and development programs and operations into 2029. Forward-Looking Statements The statement in this Item 2.02 of this Current Report on Form 8-K regarding the period through which the Company expects its cash to fund its research and development programs and operations is a forward-looking statement within the meaning of the Private Securities Litigation Reform Act of 1995. This statement is based on the Company’s current operating plans and assumptions and is subject to risks and uncertainties that could cause actual results to differ materially, including changes in the…2026-10-26SEC EDGAR 8-K 0001213900-26-112279 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-26)On October 26, 2026, the Company posted a presentation on the “Investors” section of the Company’s website (www.xencor.com), which includes a description of the updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma. The information contained in, or that can be accessed through, the Company’s website is not a part of this filing. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The presentation is current as of October 26, 2026, and the Company disclaims any obligation to update, supplement or amend this…2026-10-26SEC EDGAR 8-K 0001213900-26-112279 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-26)On October 25, 2026, the Company issued a press release announcing updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.2026-10-26SEC EDGAR 8-K 0001213900-26-112279 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-05)On August 5, 2026, Xencor, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2026 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in “Item 2.02. Results of Operations and Financial Condition” of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended…2026-08-05SEC EDGAR 8-K 0001326732-26-000055 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-07-29)On July 29, 2026, Xencor, Inc. (the “Company”) entered into a settlement agreement and release (the “Settlement Agreement”), with Alexion Pharma International Operations Limited, an Irish limited company (“Alexion”) with respect to a commercial dispute related to U.S. royalties on Ultomiris® (ravulizumab-cwvz). Pursuant to the Settlement Agreement, the Company will receive an aggregate of $105 million in two equal payments: the first $52.5 million payment is anticipated in August 2026 and the second $52.5 million payment within 14 days following the one-year anniversary of the date of the Settlement Agreement. Alexion will have no further obligation to pay royalties on U.S. sales of…2026-07-29SEC EDGAR 8-K 0001326732-26-000049 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-07-29)Based on current operating plans, the Company expects to have cash to fund research and development programs and operations through 2028. The information furnished under this Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.2026-07-29SEC EDGAR 8-K 0001326732-26-000049 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-07-29)On July 29, 2026, the Company issued a press release announcing entry into the Settlement Agreement with Alexion. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information furnished under this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.2026-07-29SEC EDGAR 8-K 0001326732-26-000049 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
Employer name (as filed)Xencor, Inc.2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 23:58 UTCReport an error
Certified LCAs12026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 23:58 UTCReport an error
Certified LCAs later withdrawn02026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 23:58 UTCReport an error
Total worker positions on certified LCAs12026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 23:58 UTCReport an error
Top job titles (title, LCA count)Manager, Corporate Strategy (1)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 23:58 UTCReport an error
Wage offered, annualized (n, min, median, max)median $139,000 (range $139,000-$139,000, 1 filings)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 23:58 UTCReport an error
Worksite statesCA2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 23:58 UTCReport an error
Plan (pension, plan no. 001)XENCOR, INC. 401(K) PLAN: 347 participants, assets $58,985,2342025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 23:58 UTCReport an error
Plan (welfare, plan no. 501)XENCOR, INC. HEALTH AND WELFARE PLAN: 264 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 23:58 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$219,785,3042026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #2 (13F as filed): PRIMECAP MANAGEMENT CO/CA/$163,919,2852026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #3 (13F as filed): BVF INC/IL$114,852,8922026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #4 (13F as filed): RTW INVESTMENTS, LP$109,117,1222026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #5 (13F as filed): RA CAPITAL MANAGEMENT, L.P.$84,915,8112026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #6 (13F as filed): STATE STREET CORP$79,759,6582026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$52,788,7122026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #8 (13F as filed): TCG Crossover Management, LLC$39,479,4222026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #9 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$35,672,6092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #10 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$30,933,1082026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.